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Abstract
Systematic interrogation of gene function requires the ability to perturb gene expression in a 
robust and generalizable manner. We describe structure-guided engineering of a CRISPR-Cas9 
complex to mediate efficient transcriptional activation at endogenous genomic loci. We use these 
engineered Cas9 activation complexes to investigate sgRNA targeting rules for effective 
transcriptional activation, demonstrate multiplexed activation of 10 genes simultaneously, and 
upregulate long intergenic non-coding RNA (lincRNA) transcripts. We also synthesize a library 
consisting of 70,290 guides targeting all human RefSeq coding isoforms to screen for genes 
which, upon activation, confer resistance to a BRAF inhibitor. Expected and potentially novel 
resistance genes are enriched in the top hits and are validated using individual sgRNA as well as 
cDNA overexpression. The signature of our top screening hits is significantly correlated with gene 
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expression data from clinical melanoma samples. These results collectively demonstrate the 
potential of Cas9-based activators as a powerful genetic perturbation technology.
Achieving systematic, genome-scale perturbations within intact biological systems is 
important for elucidating gene function and epigenetic regulation. Genetic perturbations can 
be broadly classified as either loss-of-function or gain-of-function (GOF) based on their 
mode of action. To date, various genome-scale loss-of-function screening methods have 
been developed, including approaches employing RNA interference1,2 and the RNA-guided 
endonuclease Cas9 from the microbial CRISPR (clustered regularly interspaced short 
palindromic repeat) adaptive immune system3,4. Genome-scale GOF screening approaches 
have largely remained limited to the use of cDNA library overexpression systems. However, 
it is difficult to capture the complexity of transcript isoform variance using these libraries, 
and large cDNA sequences are often difficult to clone into size-limited viral expression 
vectors. The cost and complexity of synthesizing and using pooled cDNA libraries have also 
limited their use. Novel technologies that overcome such limitations would enable 
systematic, genome-scale GOF perturbations at endogenous loci.
Programmable DNA binding proteins have emerged as an exciting platform for engineering 
synthetic transcription factors for modulating endogenous gene expression5–11. Among the 
established custom DNA binding domains, Cas9 is most easily scaled to facilitate genome-
scale perturbations3,4 due to its simplicity of programming relative to zinc finger proteins 
and transcription activator-like effectors (TALEs). Cas9 nuclease can be converted into an 
RNA-guided DNA binding protein (dCas9) via inactivation of its two catalytic domains12,13 
and then fused to transcription activation domains. These dCas9-activator fusions targeted to 
the promoter region of endogenous genes can then modulate gene expression7–11. Although 
the current generation of dCas9-based transcription activators is able to achieve up-
regulation of some endogenous loci, the magnitude of transcriptional up-regulation achieved 
by individual single-guide RNAs (sgRNAs)12 typically ranges from low to ineffective8–11. 
Tiling a given promoter region with several sgRNAs can produce more robust 
transcriptional activation9–11, but this requirement presents enormous challenges for 
scalability, and in particular for establishing pooled, genome-wide GOF screens.
In order to improve and expand applications of Cas9, we recently undertook crystallographic 
studies to elucidate the atomic structure of the Cas9-sgRNA-target DNA tertiary complex14, 
thus enabling rational engineering of Cas9 and sgRNA. Here we report a series of structure-
guided engineering efforts to create a potent transcription activation complex capable of 
mediating robust up-regulation with a single sgRNA. Using this new activation system, we 
demonstrate activation of endogenous genes as well as non-coding RNAs, elucidate design 
rules for effective sgRNA target sites, and establish and apply genome-wide dCas9-based 
transcription activation screening to study drug resistance in a melanoma model. These 
results collectively demonstrate the broad applicability of CRISPR-based GOF screening for 
functional genomics research.
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Structure-guided design of Cas9 complex
Transformation of the Cas9-sgRNA complex into an effective transcriptional activator 
requires finding optimal anchoring positions for the activation domains. Previous designs of 
dCas9-based transcription activators have relied on fusion of transactivation domains to 
either the N- or C-terminus of the dCas9 protein. To explore whether alternate anchoring 
positions would improve performance, we examined our previously determined crystal 
structure of the Streptococcus pyogenes dCas9 (D10A/H840A) in complex with a single 
guide RNA (sgRNA) and complementary target DNA14. We observed that the tetraloop and 
stem-loop 2 of the sgRNA protrude outside of the Cas9-sgRNA ribonucleoprotein complex, 
with the distal 4 bp of each stem completely free of interactions with Cas9 amino acid 
sidechains (Extended Data Fig. 1a). Based on these observations, along with functional data 
demonstrating that substitutions and deletions in the tetraloop and stem-loop 2 regions of the 
sgRNA sequence do not affect Cas9 catalytic function14 (Fig. 1a), we reasoned that the 
tetraloop and stem-loop 2 could tolerate the addition of protein-interacting RNA aptamers to 
facilitate the recruitment of effector domains to the Cas9 complex (Fig. 1b).
We selected a minimal hairpin aptamer, which selectively binds dimerized MS2 
bacteriophage coat proteins in mammalian cells, and appended it to the sgRNA tetraloop and 
stem-loop 215 (Extended Data Fig. 1b). We next tested whether MS2-mediated recruitment 
of VP64 to the tetraloop and stem-loop 2 could mediate transcriptional up-regulation more 
efficiently than a dCas9-VP64 fusion. As predicted, aptamer-mediated recruitment of MS2-
VP64 to either tetraloop (sgRNA1.1) or stem-loop 2 (sgRNA1.2) mediated 3- and 5-fold 
higher levels of Neurog2 up-regulation than a dCas9-VP64 fusion (sgRNA 1.0), 
respectively. Recruitment of VP64 to both positions (sgRNA 2.0) resulted in an additive 
effect, leading to 12-fold increase over dCas9-VP64 (sgRNA 1.0). Combining sgRNA 2.0 
with dCas9-VP64 instead of dCas9 provided an additional 1.3-fold increase in Neurog2 up-
regulation (Fig. 1c). We further compared sgRNA 2.0 to a previously-described sgRNA 
bearing two MS2-binding stem-loops at the 3` end (sgRNA + 2×MS2)11 and found that 
sgRNA 2.0 drove 14- and 8.5-fold higher levels of transcription activation than sgRNA + 
2×MS2 for ASCL1 and MYOD1, respectively (Fig. 1d). This difference could be due to 
either improved positioning of MS2 stemloops or to dCas9 protection of internal MS2 
stemloops from exonuclease degradation.
To further improve the potency of Cas9-mediated gene activation, we considered how 
transcriptional activation is achieved in natural contexts, where endogenous transcription 
factors generally act in synergy with co-factors16. We thus hypothesized that combining 
VP64 with additional, distinct activation domains could improve activation efficiency. We 
chose the NF-κB trans-activating subunit p65, which, while sharing some common co-
factors with VP64, recruits a distinct subset of transcription factors and chromatin 
remodeling complexes. For example, p65 has been shown to recruit AP-1, ATF/CREB, and 
SP117, whereas VP64 recruits PC418, CBP/p30019, and the SWI/SNF complex20.
We then varied the effector domain fused to dCas9 or MS2. Hetero-effector pairing of 
dCas9 and MS2 fusion proteins (e.g. dCas9-VP64 paired with MS2-p65 or dCas9-p65 with 
MS2-VP64) provided over 2.5-fold higher transcription activation for both ASCL1 and 
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MYOD1 than homo-effector pairing (e.g. dCas9-VP64 paired with MS2-VP64 or dCas9-p65 
with MS2-p65) (Fig. 1e). We further explored this concept of domain synergy by 
introducing the activation domain from human heat-shock factor 1 (HSF1)21 as a third 
activation domain, and found that an MS2-p65-HSF1 fusion protein further improved 
transcriptional activation of ASCL1 (12%) and MYOD1 (37%) (Fig. 1f). Additional 
modifications to the sgRNA as well as Cas9 protein, including varying the nuclear 
localization signal (NLS), provided only minor improvements (Extended Data Fig. 1c–e). 
Based on these collective results, we concluded that the combination of sgRNA 2.0, NLS-
dCas9-VP64, and MS2-p65-HSF1 comprises the most effective transcription activation 
system, and designated it synergistic activation mediator (SAM). For simplicity, we will 
refer to sgRNA 2.0 as sgRNA in subsequent discussions, unless noted otherwise.
Design rules for efficient sgRNAs
To thoroughly evaluate the effectiveness of SAM for activating endogenous gene 
transcription, we chose 12 genes that were previously found by several groups to be difficult 
to activate using dCas9-VP64 and individual sgRNA 1.0 guides8,10,11. For each gene, we 
selected 8 sgRNA target sites spread across the proximal promoter between −1000bp and the 
+1 transcription start site (TSS). For 9 out of 12 genes, the maximum level of activation 
achieved using dCas9-VP64 with any of the 8 sgRNA 1.0 guides was less than 2-fold, while 
the remaining three genes (ZFP42, KLF4 and IL1B) were maximally activated between 2- 
and 5-fold (Fig. 2a). In contrast, SAM stimulated transcription at least 2-fold for all genes 
and more than 15-fold for 8 out of 12 genes. Consistently, SAM performed better than 
sgRNA 1.0 + dCas9-VP64 for all 96 guides, with a median gain of 105-fold greater up-
regulation across all 12 genes (activation by SAM divided by activation by sgRNA 1.0).
Previous studies have demonstrated that the poor activation efficiency of single sgRNAs can 
be overcome by combining dCas9-VP64 with a pool of sgRNAs tiling the proximal 
promoter region of the target gene9–11. Therefore we compared the single sgRNA activation 
efficiency of SAM against dCas9-VP64 combined with a pool of 8 sgRNA 1.0 guides and 
MS2-effector fusions, all targeting the same gene. For most genes, SAM with a single 
sgRNA performed more robustly than dCas9-VP64 with pools of 8 sgRNA 1.0 guides (Fig. 
2b). For 9 out of 12 genes, MS2-p65-HSF1 outperformed MS2-p65 alone, and addition of 
another activation domain MyoD1 (MS2-p65-MyoD1) also improved performance 
(Extended Data Fig. 2a)
Next, we sought to determine factors that contribute to inter- and intragenic variability of 
activation efficiency by different sgRNAs. For intergene variability, differences in activation 
magnitudes could be due to epigenetic factors and/or variation in basal transcription levels. 
We were thus interested in correlating basal transcription with the level of transcription 
activation achieved using SAM. Using the relative transcriptional levels of target genes in 
control samples, we observed a highly significant correlation between the inverse of basal 
transcript level and the fold up-regulation achieved using SAM (Fig. 2c; r = 0.94, p < 
0.0001). This suggests that the basal expression level of each gene largely determines the 
level of activation.
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To study the intragenic variability of SAM activity, we aggregated the activation data for all 
96 guides and found the distance between the guide RNA target site and the TSS to be the 
strongest predictor of activation efficiency (Fig. 2d; r = 0.67, p < 0.0001). For all genes, the 
highest levels of activation were consistently achieved by targeting within the −200 bp to +1 
bp window. This simple design guideline can inform the selection of efficient sgRNAs for 
gene activation.
We also sought to test whether SAM is able to activate non-coding elements in addition to 
protein-coding genes. We chose a diverse set of 6 lincRNAs and found that SAM mediated 
significant up-regulation of each target (Fig. 2e), with MS2-p65-HSF1 or MS2-p65-MyoD1 
leading to the highest levels of activation for each lincRNA (p < 0.01) (Extended Data Fig. 
3). We also examined the effect of the most potent sgRNA for each lincRNA on the 
transcription of the nearest coding gene. Of all sgRNAs tested, only the sgRNA targeting 
HOTTIP – the only sgRNA located within 500bp of the neighboring gene’s TSS – led to 
significant activation of its neighbor (Extended Data Fig. 2b).
Multiplex gene activation
The ability to simultaneously modulate gene expression at multiple loci would allow a better 
understanding of complex genetic and regulatory networks. Using sets of 2 to 10 sgRNAs, 
we observed successful activation of all target genes (>2-fold) within all sgRNA 
combinations (Fig. 3a and 3b and Extended Data Fig. 4). As expected, most genes 
(excluding IL1R2) exhibited a decrease in the amount of up-regulation achieved when 
concurrently targeted with 9 other genes. Interestingly, the relative activation levels of each 
gene changed between multiplex activation and single-gene activation experiments (Fig. 3a 
and b).
We asked if reduced activation of targets during multiplexing was due to the reduced 
amounts of sgRNA or SAM protein components. Surprisingly, diluting the sgRNA 
expression plasmid by 10-fold in single-gene activation experiments did not reduce 
activation for all genes (Fig. 3c). We found that genes whose levels of activation are reduced 
upon sgRNA dilution also exhibited dampened levels of activation when multiplexed (Fig. 
3d; r = 0.94, p<0.001). In contrast, the activation efficiency of SAM was generally 
unperturbed by dilution of its protein components (dCas9-VP64 and MS2-p65-HSF1) 
(Extended Data Fig. 5). Activation efficiency remained stable particularly when all three 
components were diluted, retaining on average 90% activation efficiency across a 50-fold 
dilution range (Extended Data Fig. 5). This finding was particularly promising for genome-
scale pooled screening applications, which rely on single-copy lentiviral integration.
Specificity of SAM-mediated activation
An important consideration for SAM use is its targeting specificity. Recent analysis of 
genome-wide dCas9-binding revealed significant concentration-dependent off-target 
binding22, yet its effect on the specificity of transcription modulation remains unclear. To 
assess SAM specificity, we chose HBG1/2 as our target gene, reasoning that globin genes 
would have few downstream targets that could confound our specificity analysis. We found 
that SAM specifically activated both HBG1 and HBG2 isoforms (p < 0.05, T-test after 0.01 
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FDR correction), which share the same TSS (Fig. 4 and Extended Data Fig. 6), while no 
other genes were found to be differentially expressed. We also tested two additional non-
targeting sgRNAs with guide sequences that do not share perfect homology with the human 
genome. We found only two genes, S100A1 and CYB5R2, to be differentially expressed (p < 
0.05, T-test after 0.01 FDR correction for multiple hypothesis testing) compared with GFP-
expressing control (Extended Data Fig. 6) for both non-targeting guides. These results 
suggest that SAM-mediated gene activation is specific with minimal off-target activity.
Genome-scale gene activation screen
The ability to activate target genes using individual sgRNAs greatly facilitates the 
development of pooled, genome-scale transcriptional activation screening. To develop a 
SAM-based screening system, we generated lentiviral expression vectors that are able to 
drive robust transcription activation at low multiplicity of infection (MOI) (Extended Data 
Fig. 7a,b). Using this lentiviral system, we generated a genome-scale sgRNA library 
consisting of 70,290 guides, targeting every coding isoform from the RefSeq database 
(23,430 isoforms). For each gene, 3 sgRNAs were chosen to target sites within 200 bp 
upstream of the TSS, which was previously determined to provide more efficient activation 
(Fig. 2d and Fig. 5a).
Previously we applied genome-scale CRISPR knockout (GeCKO) library3 in A375 
(BRAFV600E) melanoma cells to identify loss-of-function mutations capable of mediating 
resistance against the BRAF inhibitor PLX-4720. Here we sought to use the new SAM 
sgRNA library to identify a complementary set of gain-of-function changes that can confer 
BRAF inhibitor resistance (Fig. 5a). At 14-days post drug treatment, the sgRNA distribution 
was significantly different between cells treated with PLX-4720 and with vehicle, with the 
majority of sgRNAs exhibiting a reduced representation and a small set of guides showing 
high enrichment for PLX-4720 treated cells (Fig. 5b and Extended Data Fig. 7c). For a 
number of gene targets, multiple sgRNAs targeting the same gene were enriched in 
PLX-4720-treated cells (Fig. 5c) and the 10 most significant hits were distributed throughout 
the genome (Fig. 5d and Extended Data Fig. 7d). The significance of the p-values of our top 
100 RIGER hits (Supplementary Table 1 and 2) was comparable to those observed for 
GeCKO screening3 (Fig. 5e). In addition, for the top 10 shared hits between two 
independent screens (Zeo and Puro selection for sgRNA expression), the fraction of 
effectively enriched guides per gene (present in the top 5% of all guides) was very high with 
97% for Zeo and 81% for Puro (89% ± 10.7% overall, compared to 78% ± 27% for the top 
10 GECKO hits, Fig. 5f and Extended Data Fig. 7e).
Our screen results highlight a number of gene candidates that both confirm known 
PLX-4720 resistance pathways and suggest new mechanisms (Extended Data Fig. 7f). First, 
reactivation of the ERK pathway is one of the main known resistance mechanisms23,24, and 
two of our screening hits, BCAR3 and EGFR, likely modulate downstream and upstream 
nodes of this pathway, respectively25,26. EGFR has been previously validated as a mediator 
of resistance to PLX-4720 through PI3K and AKT, in addition to ERK26,27. These two 
pathways are thought to be alternative routes of PLX-4720 resistance24,28,29. Furthermore, 
four out of the top 10 hits from our screen belong to the family of G protein-coupled 
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receptors (GPCRs: GPR35, LPAR1, LPAR5, and P2RY8), which emerged as the top-ranked 
protein class conferring resistance to multiple MAP kinase inhibitors in melanoma cells in a 
recent screen using cDNA overexpression30. GPCRs signal through multiple downstream 
pathways including ERK, PI3K, as well as cAMP and PKA31,32. The final class of protein 
candidates from our screen belongs to the ITG receptor family, which is thought to interact 
with RTK and activate both ERK and PI3K pathways33,34.
To verify the results from the PLX-4720 resistance screen, we validated each of the top 13 
genes. All sgRNAs from the screen that targeted these 13 genes conferred PLX-4720 
resistance when individually expressed in A375 along with SAM (Fig. 6a and Extended 
Data Fig. 8a). We also verified that SAM was able to facilitate robust increase in target 
transcript (Fig. 6a and Extended Data Fig. 8b) and protein levels (Fig. 6a). Since 5 of our top 
candidates from the pooled SAM screen overlapped with hits from a previously conducted 
arrayed cDNA screen30 (Extended Data Fig. 8c), we compared the relative efficacy of 
cDNA overexpression with SAM-mediated transcription activation. Interestingly, for these 5 
targets, SAM led to at least similar levels of PLX-4720 resistance when compared with 
corresponding cDNA overexpression conditions (Extended Data Fig. 8a), despite cDNA 
leading to higher transcript levels (Extended Data Fig. 8d). Furthermore, we found that, for 
most genes, the levels of PLX-4720 resistance mediated by all three sgRNAs were 
comparable (Extended Data Fig. 8e).
In addition to validating our top screening hits through individual sgRNA or cDNA 
overexpression, we analyzed the expression profile of our screening hits using four different 
datasets (CCLE35, TCGA: https://tcga-data.nci.nih.gov/tcga/, short-term melanoma36,37, and 
pre/post treatment patient samples38). As shown previously39, a distinct transcriptional state 
defines BRAF-inhibition sensitive and resistant states as described by activation of 
endogenous MITF/associated markers (e.g. PMEL) and NF-κB-pathway activity/associated 
markers (e.g. AXL), respectively (Fig. 6b and Extended Data Fig. 9b). Based on short-term 
melanoma data fom the Cancer Genomics Hub37,39, we found that the expression of our top 
screening hits was significantly increased in the resistant state. Correspondingly, a gene 
expression signature derived from the top screening hits was correlated with BRAF-inhibitor 
resistance (Fig. 6b; total overlap, p < 0.0001). Further analysis performed using the CCLE, 
TCGA, and pre/post treatment data set also revealed similar correlations (Extended Data 
Fig. 9).
Discussion
In summary, we have taken a structure-guided approach to design a dCas9-based 
transcription activation system for achieving robust, single sgRNA-mediated gene up-
regulation. By engineering the sgRNA to incorporate protein-interacting aptamers, we 
assembled a synthetic transcription activation complex consisting of multiple distinct 
effector domains modeled after natural transcription activation processes. Here we have 
shown that the SAM system is robust, specific, and can facilitate genome-scale gain-of-
function screening when combined with a compact pooled sgRNA library. Our SAM-
mediated screens exhibited a high degree of consistency and validation, with 80% 
effectively enriched guides per gene hit, and 100% validation of the top 10 hits.
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Future engineering of the Cas9 complex based on structural information14,40 will further 
expand the Cas9 toolbox41. Additional developments of the SAM system may be able to 
take advantage of the modularity and customizability of the sgRNA scaffold to establish a 
series of sgRNA scaffolds bearing different aptamers for recruiting distinct types of 
effectors in an orthogonal manner. For instance, replacement of the MS2 stem-loops with 
PP7-interacting stem-loops may be used to recruit repressive elements, potentially enabling 
multiplexed bidirectional transcriptional control. Although we have taken initial steps 
toward defining selection rules for potent sgRNAs, future studies will reveal additional 
selection criteria that are critical for guide efficacy, such as sequence-intrinsic properties 
(Extended Data Fig. 10a–d). Applications of dCas9-based transcription modulators in 
positive and negative selection screens (Extended Data Fig. 10e–f)42 will enable the 
dissection of many types of genetic elements, ranging from protein-coding genes to non-
coding lincRNA elements. Furthermore, combining wildtype Cas9-mediated genome 
modifications with SAM-mediated recruitment of epigenetic modifiers will constitute 




DNA sequences for SAM components sgRNA scaffolds are provided in Supplementary 
Sequences. sgRNA target sequences for characterization and optimization of SAM are listed 
in Supplementary Table 4.
Transient transfection experiments
Neuro-2a cells (Sigma-Aldrich) were grown in media containing 1:1 ratio of OptiMEM 
(Life Technologies) to high-glucose DMEM with GlutaMax and sodium pyruvate (Life 
Technologies) supplemented with 5% HyClone heat-inactivated FBS (Thermo Scientific), 
1% penicillin/streptomycin (Life Technologies), and passaged at 1:5 every 2 days.
HEK293FT cells (Life Technologies) were maintained in high-glucose DMEM with 
GlutaMax and sodium pyruvate (Life Technologies) supplemented with 10% heat-
inactivated characterized HyClone fetal bovine serum (Thermo Scientific) and 1% 
penicillin/streptomycin (Life Technologies). Cells were passaged daily at a ratio 1:2 or 
1:2.5. For gene activation experiments, 20,000 HEK293FT cells/well were plated in 100 µL 
media in poly-D-lysine coated 96-well plates (BD BioSciences). 24 hours after plating, cells 
were transfected with a 1:1:1 mass ratio of:
• sgRNA plasmid with gene-specific targeting sequence or pUC19 control plasmid
• MS2-effector plasmid or pUC19.
• dCas9 plasmid, dCas9-effector plasmid, or pUC19.
A total plasmid mass of 0.3 µg/well was transfected using 0.6 µL/well Lipofectamine 2000 
(Life Technologies) according to the manufacturer’s instructions. Culture medium was 
changed 5 hours after transfection. 48 hours after transfection, cell lysis and reverse 
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transcription were performed using a Cells-to-Ct kit (Life Technologies). Relative RNA 
expression levels were quantified by reverse transcription and quantitative PCR (qPCR) 
using TaqMan qPCR probes (Life Technologies, Supplementary Table 5) and Fast 
Advanced Master Mix (Life Technologies). qPCR was carried out in 5 µL multiplexed 
reactions and 384-well format using the LightCycler 480 Instrument II. Data was analyzed 
by the ΔΔCt method: target Ct values (FAM dye) were normalized to GAPDH Ct values 
(VIC dye), and fold changes in target gene expression were determined by comparing to 
GFP-transfected experimental controls.
Lentivirus production
HEK293T cells (Life Technologies) were cultured as described above for HEK293FT cells. 
1 day prior to transfection, cells were seeded at ~40% confluency (12×T225 flasks for 
library scale production, 1×T25 flask for individual guide production). Cells were 
transfected the next day at ~80–90% confluency. For each flask, 10 µg of plasmid 
containing the vector of interest, 10 µg of pMD2.G, and 15 µg of psPAX2 (Addgene) were 
transfected using 100 µL of Lipofectamine 2000 and 200 µL Plus Reagent (Life 
Technologies). 5h after transfection the media was changed. Virus supernatant was 
harvested 48h post-transfection, filtered with a 0.45 µm PVDF filter (Millipore), aliquoted, 
and stored at −80 °C.
Lentiviral transduction
A375 cells (ATCC) were cultured in RPMI 1640 (Life Technologies) supplemented with 
10% FBS (Seradigm) and 1% penicillin/streptomycin (Life Technologies) and passaged 
every other day at a 1:4 ratio. Cells were transduced with lentivirus via spinfection in 12-
well plates. 3 × 106 cells in 2 mL of media supplemented with 8 µg/mL polybrene (Sigma) 
were added to each well, supplemented with lentiviral supernatant and centrifuged for 2h at 
1000g. 24h after spinfection, cells were detached with TrypLE (Life Technologies) and 
counted. Cells were replated at low density (7.5 × 106 cells per T225 Flask) and a selection 
agent was added either immediately (Zeocin, Blasticidin and Hygromycin, all Life 
Technologies) or 3h after plating (Puromycin). Concentrations for selection agents we 
determined using a kill curve: 0.5 µg/ml Puromycin, 200 µg/mL Zeocin, 10 µg/mL 
Blasticidin, and 300 µg/mL Hygromycin. Media was refreshed on day 2 and cells were 
passaged every other day starting on day 4 after replating. The duration of selection was 4 
days for Puromycin and 7 days for Zeocin, Hygromycin and Blasticidin. Lentiviral titers 
were determined by spinfecting cells with 6 different volumes of lentivirus ranging from 0 
to 600 µL and counting the number of surviving cells after a complete selection (3–6 days).
Design and Cloning of SAM library
RefSeq coding gene isoforms with a unique TSS (total of 23’430 isoforms) were targeted 
with three guides each for a total library of 70,290 guides (Supplementary Table 6). Guides 
were designed to target the first 200 bp upstream of each TSS and subsequently filtered for 
GC content >25% and minimal overlap of the target sequence. After filtering, the remaining 
guides were scored according to predicted off-target matches as described previously43, and 
three guides with the best off-target scores were selected. Cloning of the SAM sgRNA 
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libraries was performed as previously described3 with a minimum representation of 100 
transformed colonies/guide.
Depletion and PLX-4720 Screen
A375 cells stably integrated with SAM Cas9 and effector components were transduced with 
SAM sgRNA libraries as described above at an MOI of 0.2, with a minimal representation 
of 500 transduced cells/guide. Cells were maintained at >500 cells/guide during subsequent 
passaging. At 7 DPI (complete selection, see above), cells were split into vehicle (DMSO) 
and PLX-4720 conditions (2 µM PLX-4720 dissolved in DMSO, Selleckchem). Cells were 
passaged every 2 days for a total of 14 days of drug treatment. >500 cells/guide were 
harvested as a baseline at 3 DPI (4 days before treatment) and at 21 DPI (after 14 days of 
treatment) for gDNA extraction. Genomic DNA was extracted using the Zymo Quick-
gDNA midi kit (Zymo Research). PCR of the virally integrated guides was performed on 
gDNA at the equivalent of >500 cells/guide in 96 parallel reactions using NEBnext High 
Fidelity 2× Master Mix (New England Biolabs) in a single-step reaction of 22 cycles. 
Primers are listed below:
PCR products from all 96 reactions were pooled, purified using Zymo-Spin™ V with 
Reservoir (Zymo research) and gel extracted using the Zymoclean™ Gel DNA Recovery Kit 
(Zymo research). Resulting libraries were deep-sequenced on Illumina MiSeq and HiSeq 
platforms with a total coverage of >35 million reads passing filter per library.
NGS and screen hits analysis
NGS data were de-multiplexed using unique index reads. Guide counts (Supplementary 
Table 7) were determined based on perfectly matched sequencing reads only. For each 
condition, guide counts were normalized to the total number of counts per condition, and 
log2 counts were calculated based on these values. Ratios of counts between conditions were 
calculated as log2((count 1 + 1)/(count 2 +1)) based on normalized counts.
RIGER analysis was performed using GENE-E based on the normalized day 14 log2 ratios 
(PLX-4720/DMSO) averaged over two independent infection replicates. All RIGER 
analysis used the Kolmogorov-Smirnov method as described previously44, except for Fig. 
6c, where the weighed average method was used in order to enable comparison to GeCKO 
values determined by that method.
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Gene expression and Pharmacological Validation Analysis
Gene expression data (CCLE, TCGA, short-term cultures, patient melanoma biopsies) and 
pharmacological data (CCLE, short-term cultures) were analyzed to better understand the 
biological relevance of the top gene hits from the SAM screens. In the CCLE dataset35, gene 
expression data (RNA-sequencing, GCHub: https://cghub.ucsc.edu/datasets/ccle.html) and 
pharmacological data (activity area for MAPK pathway inhibitors) from BRAFV600 mutant 
melanoma cell lines were used to compute the association between PLX-4720 resistance and 
the gene expression of each of the top hits. Additionally, gene expression signatures 
comprised of the top hits were generated using single-sample Gene Set Enrichment Analysis 
(ssGSEA)45, and the associations between PLX-4720 resistance and these signatures were 
computed.
Gene expression data (Affymetrix GeneChip HT-HGU133) and PLX-4720 pharmacological 
data (GI50; only for a subset of the samples) from short term melanoma cultures (STC)36 
was also used for plotting the gene expression of top hits and their ssGSEA signature scores. 
Expression data for the STC samples were collapsed to maximum probe value per gene and 
preprocessed using robust spline normalization.
Gene expression (RNA-sequencing) and genotyping data were collected from 113 
BRAFV600-mutant primary and metastatic patient tumors from The Cancer Genome Atlas 
(https://tcga-data.nci.nih.gov/tcga/) and this data was similarly used for determining the 
association between resistance and the expression of top hits/ssGSEA signature scores. 
Because pharmacological data was not available for the STCs (only a subset had PLX-4720 
data) and the TCGA melanoma samples, a transcriptional state was plotted using marker 
genes and signatures39 in order to identify samples resistant to BRAF-inhibition.
Gene expression data from 13 patients with BRAFV600E melanomas38 was used for 
analyzing the relationship between resistance and the expression of our top hits/ssGSEA 
signature scores. Because all the post-treatment tumors were resistant and not every sample 
had a paired on-treatment biopsy, we decided to order the samples by MITF expression in 
the pre-treatment samples to reflect the original PLX-4720 sensitivity state of the tumors. 
We then used the expression data in the post-treatment resistant tumors to plot the 
expression of top hits/ssGSEA signature scores. We also calculated the log2-fold change 
between each patient’s post/pre paired samples and determined the number of patients that 
had at least a log2-fold change of 2 per top screen hit.
Single Sample Gene Set Enrichment Analysis
While there was a significant association between the overexpression of some of our top 
individual SAM screen hits and resistance in three external cancer datasets, we sought a 
more robust scoring system independent of any single gene. Gene expression signatures 
were generated based on the set of top hits from each of the two SAM screens and for the 
overlap between them. Using single-sample Gene Set Enrichment analysis (ssGSEA), a 
score was generated for each sample that represents the enrichment of the SAM screen gene 
expression signature in that sample and the extent to which those genes are coordinately up- 
or down-regulated. Additionally, signature gene sets from the Molecular Signature Database 
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(MSigDB)46 were used in order to fully map the transcriptional BRAF-inhibitor resistant/
sensitive states in the short-term culture and TCGA datasets as previously described39.
Information Coefficient for Measuring Associations in External Datasets
To measure correlations between different features (signature scores, gene expression, or 
drug-resistance data) in the external cancer datasets, an information-theoretic approach 
(Information Coefficient; IC) was used and significance was measured using a permutation 
test (n=10,000), as previously described39. The IC was calculated between the feature used 
to sort the samples (columns) in each dataset and each of the features plotted in the heatmap 
(pharmacological data, gene expression, and signature scores).
sgRNA sequence analysis
Depletion for each sgRNA was calculated as the ratio of counts (see “NGS and screen hits 
analysis”) between day 3 and day 21. The sgRNAs corresponding to genes with significant 
depletion (p < 0.05 by RIGER analysis) in sgRNA-Puro and sgRNA-Zeo libraries were 
selected for analyses. These sgRNAs were analyzed for nucleotide occurrence in the sgRNA 
sequence, distance from TSS, and guide strand relative to transcript orientation. For each 
variable, the correlation and significance with the sgRNA ratio was calculated by Ordinary 
Least Squares linear regression.
PLX-4720 Survival Assay
A375 cells stably integrated with dCas9-VP64 and MS2-p65-HSF1 were transduced with 
individual guides from the top screening hits of the Zeocin and Puromycin screens (13 genes 
total, 3 sgRNAs per gene) as well as available cDNA at an MOI of <0.2 as described above. 
Cells were selected for guide expression with Zeocin (Life Technologies) for 5 days and 
replated at low density (3 × 103 cells per well in a 96-well plate). A375 cells and A375 cells 
expressing dCas9-VP64 and MS2-p65-HSF1 were plated as controls. Different 
concentrations of PLX-4720 (2µM, 0.5µM, 0.15µM) or vehicle (DMSO) were added 3h after 
plating. Cells were treated with PLX-4720 for 4 days before cell viability was measured 
using CellTiter-Glo Luminescent Cell Viability Assay (Promega). For qPCR quantification 
of target gene upregulation, cells were also plated at 5 DPI (3 × 104 cells per well in a 96-
well plate) and harvested for mRNA 24h after plating.
Western Blot
Protein lysates were prepared with RIPA lysis buffer (Cell Signaling Technologies) 
containing a protease inhibitor cocktail (Roche). Samples standardized for protein with the 
Pierce BCA protein assay (Thermo Scientific) were boiled at 95°C for 5 mins under 
reducing conditions (except for GPR35 samples, which were incubated at 37°C for 30 mins). 
After denaturation, samples for probing proteins with lower or higher molecular weight were 
separated by 10–20% or 4–15% Criterion Tris-HCl gels (Bio-Rad) and electrotransferred 
onto a 0.2µm or 0.45µm polyvinylidene difluoride membrane (Millipore) respectively. Blots 
were blocked with 5% BLOT-QuickBlocker (VWR) and probed with different primary 
antibodies [anti-EGFR (rabbit polyclonal, SC-03, Santa Cruz Biotechnology, 1:1000 
dilution), anti-PCDH7 (rabbit polyclonal, HPA011866, Sigma-Aldrich, 1:1000 dilution), 
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anti-ITGB5 (rabbit polyclonal, SC-14010, Santa Cruz Biotechnology, 1:500 dilution), anti-
ARHGEF1 (rabbit polyclonal, 11363-1-AP, Proteintech, 1:5000 dilution), anti-BCAR3 
(rabbit polyclonal, A301-671A, Bethyl Laboratories, 1:2000 dilution), anti-GPR35 (rabbit 
polyclonal, 10007660, Cayman Chemical, 1:1000 dilution), anti-TFAP2C (rabbit polyclonal, 
2320, Cell Signaling Technology, 1:1000 dilution, 2.5% bovine serum albumin, Sigma-
Aldrich)] in 2.5% BLOT-QuickBlocker (VWR) unless noted otherwise overnight at 4°C. 
Blots were then incubated with secondary antibody HRP-conjugated goat anti-rabbit IgG 
(7074, Cell Signaling Technology, 1:1000 dilution) and HRP-conjugated GAPDH (rabbit 
monoclonal, 3683, Cell Signaling Technology, 1:2000 dilution) in 2.5% BLOT-
QuickBlocker (VWR) for 1hr at room temperature. Proteins with molecular weights similar 
to GAPDH (GPR35 and TFAP2C) were stripped with Restore Plus Western Blot Stripping 
Buffer (Thermo Scientific) before probing for GAPDH. SuperSignal West Pico and Femto 
Chemiluminescent Substrates (Thermo Scientific) were used for detection.
RNA Sequencing and Data Analysis
Samples harvested for RNA sequencing were prepped with TruSeq Stranded mRNA Sample 
Prep Kit (Illumina) and deep-sequenced on the Illumina MiSeq platform (>9 Mio reads per 
condition). Bowtie247 index was created based on the human hg19 UCSC genome and 
known gene transcriptome, and paired-end reads were aligned directly to this index using 
Bowtie2 with command line options “-q --phred33-quals -n 2 -e 99999999 -l 
25 -I 1 -X 1000 -a -m 200 –p 4 --chunkmbs 512”. Next, RSEM v1.2748 was run 
with default parameters on the alignments created by Bowtie2 to estimate expression levels. 
RSEM’s gene level expression estimates (tau) were multiplied by 1,000,000 to obtain 
transcript per million (TPM) estimates for each gene, and TPM estimates were transformed 
to log-space by taking log2(TPM+1). The normalization between libraries was tested using 
an MA plot (mairplot function in Matlab V2013b). Genes were considered detected if their 
transformed expression level was equal to or above 1 (in log2(TPM+1) scale). All genes 
detected in at least one library (out of three libraries per condition) were used to construct 
scatter plots comparing each of the six conditions to the control GFP condition, using the 
average across biological replicates with >80% alignment to the hg19 UCSC known gene 
transcriptome (log2(mean(TPM)+1) value per gene).
To find differentially expressed genes, we performed Student’s t-test on each of the six 
conditions against the GFP condition. The t-test was run on all genes that had expression 
levels above log2(TPM+1)>2.5 in at least two libraries. This threshold was chosen as the 
minimal threshold for which the number of detected genes across all libraries was constant. 
Only genes that were significant (p-value pass 0.01 FDR correction) and had at least 1.5 fold 
change were reported and visualized using a heatmap.
Konermann et al. Page 13














Extended Data Figure 1. Structure-guided engineering of Cas9 sgRNA
a, Schematic of the sgRNA stem-loops showing contacts between each stem-loop and Cas9. 
Contacting amino acid residues are highlighted in yellow. Tetraloop and stem-loop 2 do not 
make any contacts with Cas9 whereas stem-loops 1 and 3 share extensive contacts with 
Cas9. b, sgRNA 2.0 with MS2 stem-loops inserted into the tetraloop and stem-loop 2. c, 
Addition of a second NLS or an alternative HNH domain inactivating point mutation in 
Cas9 improve efficiency of transcription activation for MYOD1 moderately. d, dCas9-VP64 
activators exhibit improved performance by recruitment of MS2-p65 to the tetraloop and 
stem-loop 2. Addition of an AU flip or extension in the tetraloop does not increase the 
effectiveness of dCas9-mediated transcription activation. e, Tetraloop and stem-loop 2 are 
amenable to replacement with MS2 stem-loops. Base changes from the sgRNA 2.0 scaffold 
are shown at the respective positions, with dashes indicating unaltered bases and bases 
below dashes indicating insertions. Deletions are indicated by absence of dashes at 
respective positions. All figures are n = 3 and mean ± SEM.
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Extended Data Figure 2. SAM mediates efficient activation of a panel of 12 coding genes and 6 
lincRNAs
a, Comparison of the activation levels of 12 genes with dCas9-VP64 in combination with 
MS2-p65, MS2-p65-HSF1, or MS2-p65-MyoD1. MS2-p65-HSF1 mediated significantly 
higher levels of activation than MS2-p65 alone for 9 out of 12 genes. The best guide out of 8 
tested for each gene (Fig. 2a) was used in this experiment. Activation levels for each type of 
MS2-fusion is presented as a percentage relative to the activation achieved using MS2-p65. 
b, Investigation of transcriptional changes in the closest coding transcripts for SAM-
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mediated activation of 6 lincRNAs. Direction of the coding transcript relative to the 
lincRNA and distance between transcription start sites are shown. Only targeting of 
HOTTIP resulted in a significant change in the levels of the closest coding transcript 
(HOXA13). The best guide out of 8 tested for each gene (Fig. 2e) in combination with 
dCas9-VP64 and MS2-p65-HSF1 was used in this experiment. All figures are n = 3 and 
mean ± SEM.
Extended Data Figure 3. Activation of lincRNAs by SAM
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Six lincRNAs, three characterized and three uncharacterized, were targeted using SAM. For 
each lincRNA, 8 sgRNAs were designed to target the proximal promoter region (+1 to 
−800bp from the TSS) with 4 different MS2 activators (MS2-p65-HSF1, MS2-p65-MyoD1, 
MS2-p65, and MS2-VP64) in combination with dCas9-VP64. MS2 activators with a 
combination of 2 different domains (MS2-p65-HSF1 or MS2-p65-MyoD1) consistently 
provided the highest activation for each lincRNA, * denotes p < 0.01 for MS2-p65-HSF1 or 
MS2-p65-MyoD1 vs. MS2-p65. N = 3 and mean ± SEM is shown.
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Extended Data Figure 4. Multiplexed activation using SAM and activation of a panel of 10 genes 
as a function of SAM component dosage
a, Activation of a panel of 10 genes by combinations of 2, 4, 6, or 8 sgRNAs 
simultaneously. The mean fold up-regulation is shown on a log10 scale. MS2-p65-HSF1 and 
dCas9-VP64 were used in this experiment. b, The relative activation efficiency of individual 
sgRNAs varies depending on the target gene and the degree of multiplexing. N = 3 and 
mean ± SEM is shown.
Extended Data Figure 5. The effect of guide and SAM-component dilution on target activation
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a, The results for dilution of sgRNA 2.0 on target activation. b, The result for dilution of 
sgRNA 1.0 on target activation. # denotes an activation of < 2-fold at 1× guide dilution. c, 
Effect of MS2-p65-HSF1 and dCas9-VP64 dilution, at 1:1, 1:4, 1:10, and 1:50 of the 
original dosage for each component, on the effectiveness of transcription up-regulation. The 
amount of sgRNA expression plasmid was kept constant. d, Effect of diluting all three SAM 
components (dCas9-VP64, MS2-p65-HSF1, and sgRNA) at 1:4, 1:10, and 1:50 of the 
original dosage for each component. Fold up-regulation is calculated using GFP-transfected 
cells as the baseline. Error bars indicate S.E.M. and N = 3 for all figures.
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Extended Data Figure 6. RNA-seq analysis of transcriptome changes mediated by SAM
a, A heat map of log(TPM) expression values of all statistically significant differentially 
expressed genes (T-test q-value < 0.05 adjusted with FDR multiple hypothesis correction) 
found in any of the six experimental conditions compared to the GFP-transfected control. b, 
Expression levels in log(TPM) values of all detected genes in RNA-seq libraries of GFP-
transfected controls (x-axis of all graphs) compared to (from left to right): non-targeting 
control sgRNA #2 in 1× dilution and 50× dilution (y-axis). Marked are HBG1 (red) and 
HGB2 (blue).
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Extended Data Figure 7. Genome-scale lentiviral screen using Puromycin-resistant SAM sgRNA 
library
a, Design of three lentiviral vectors for expressing sgRNA, dCas9-VP64, and MS2-p65-
HSF1. Each vector contains a distinct selection marker to enable co-selection of cells 
expressing all three vectors. b, Lentiviral delivery of SAM components was tested by first 
generating 293FT cell lines stably integrated with dCas9-VP64 and MS2-p65-HSF1, and 
subsequently transducing these cells with single-gene targeting lentiviral sgRNAs at MOI 
<0.2. Transcription activation efficiency is measured 4 days post sgRNA lentivirus 
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transduction and selection with Zeocin or Puromycin. Activation is at least as effective as 
previously observed with transient transfection in all three cases. c, Box plot showing the 
distribution of sgRNA frequencies at different time points post lentiviral transduction with 
the Puromycin library, after treatment with DMSO vehicle or PLX-4720. Two infection 
replicates are shown. d, Identification of top candidate genes using the RIGER P value 
analysis (KS method) based on the average of both infection replicates. Genes are organized 
by positions within chromosomes. e, Overlap between the top 20 hits from the Zeo and Puro 
screens. Genes belonging to the same family are indicated by the same color. There is a 50% 
overlap between the top hits of each screen as shown in the intersection of the Venn 
diagram. f, Relevant signaling pathways in BRAF inhibitor resistance. Reactivation of the 
Ras-ERK pathway as well as the parallel PI3K-Akt pathway have previously been 
implicated as two alternative resistance mechanisms to BRAF inhibitors23,24,26–29. Both 
pathways have been described as stimulating proliferation and survival49. BAD, FOXO and 
p27 are common inhibited downstream targets49. Recently, stimulation of the cAMP - 
CREB pathway by GPCRs has been described as a potential additional resistance 
mechanism30. Top candidates from our screen are indicated in blue and putative connections 
to all three pathways are shown25,50,51. Candidates previously validated to mediate 
PLX-4720 resistance are underlined in green26,30. COT and CREB are independently 
validated mediators of resistance23,30.
Konermann et al. Page 22













Extended Data Figure 8. Individual validation of PLX-4720 resistance mediation by top screen 
hits
a, Validation of the top 10 Zeo screen hits and the top 10 shared hits (13 genes total). Every 
gene was independently activated by all three guides from the screen and tested for the 
ability to increase survival of A375 cells treated with three different concentrations of 
PLX-4720 (2µM, 0.5µM and 0.15µM). The z-score based on the % increase in survival 
relative to control (A375 cells transduced with dCas9-VP64 and MS2-p65-HSF1 alone) is 
shown for each guide and PLX-4720 concentration. Five cDNAs available from a previous 
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large-scale gain-of-function PLX-4720 resistance screen were also included30. Every guide 
for each top hit mediates significant PLX-4720 resistance. b, The same panel of top hits 
exhibits a large range of basal expression levels and is effectively activated by all guides. 
The expression level relative to the housekeeping gene GAPDH is shown both at baseline as 
well as after activation by each individual guide. c, Ranks of the validated set of genes in the 
previous ORF screen. Six genes were not part of the cDNA library, five hits are shared 
(present in the top 3%) and only LPAR5 and ARHGEF1 were present but not highly ranked. 
Both of these genes had highly ranked members of the same family. d, Levels of 
overexpression from the five tested cDNA constructs. Transcript levels were higher for these 
five cDNAs than those mediated by SAM for the same genes. e, Correlation of survival at 
2µM PLX-4720 treatment and transcript upregulation achieved by individual guides. For 
most genes (9 out of 12 shown), the percent survival is very similar across transcript levels 
achieved by all three guides. Dotted lines indicate control survival.
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Extended Data Figure 9. Expression of top hits and screen signatures are elevated in PLX-4720 
resistant melanoma cell lines and patient samples
a, Heat map showing sensitivity to different drugs (top), expression of SAM top screen hits 
(middle), and SAM screen signature scores (bottom; see Online Methods for signature 
generation) in Cancer Cell Line Encyclopedia cell lines35. Drug sensitivities are measured as 
Activity Areas (AA). The melanoma cell lines are sorted by PLX-4720 drug sensitivity. 
RAF inhibitors: PLX-4720 and RAF265; MEK inhibitors: AZD6244 and PD-0325901. b, 
Heat map showing expression of gene/signature markers for BRAF-inhibitor sensitivity 
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(top), expression of SAM top screen hits (middle) and screen signature scores (bottom) in 
different BRAFV600 patient melanoma samples (primary or metastatic) from The Cancer 
Genome Atlas. c, Heat map showing MITF expression (top), screen signature scores 
(middle), and expression of SAM top screen hits (bottom) in different BRAFV600E patient 
melanoma biopsies post-treatment with BRAF inhibitors38. d, Bar chart showing the number 
of patients from (c) with at least a two-fold change (post/pre treatment) in gene expression 
of the top PLX-4720 screen hits in the post-treatment samples. All associations are 
measured using the information coefficient (IC) between the index and each of the features 
and P values are determined using a permutation test. All heat maps show z-scores.
Extended Data Figure 10. Guide depletion analysis to identify gene set enrichment and guide 
efficiency parameters
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a, Heat maps of sgRNA nucleotide content versus depletion after 21 days. sgRNA targeting 
significantly depleted genes (from RIGER analysis) in sgRNA-zeo (a) or sgRNA-puro (b) 
screens were analyzed for trends based on G or T content in the sgRNA sequence. sgRNA 
depletion is positively correlated with G content and negatively correlated with T content. 
Other bases analyzed (A and C) had significant (p < 0.0007) but weak (r < 0.2) negative 
correlation. c, 90% of guides analyzed fall within a 100bp window <200bp from the TSS. 
Boxplots of distance from 5’ end of the guide to the TSS for sgRNA-zeo and sgRNA-puro 
in same and reverse direction (relative to target transcription). Whiskers span 5th to 95th 
quartile. d, Coefficients and P values for ordinary least squares predicting sgRNA depletion 
of significantly depleted genes from G content, T content, distance from 5’ end of the guide 
to the TSS and direction of guide. Only nucleotide content has a significant effect on 
depletion in this model, consistent with a high efficiency of guides within 200bp of the TSS 
regardless of strand orientation (Fig. 2d). e, The cumulative frequency of sgRNAs 3 and 21 
days after transduction in A375 cells is shown. Shift in the 21-day curve represents the 
depletion in a subset of sgRNAs. Less than 0.1% of all guides are not detected at day 3 
(detected by less than 10 reads). f, Depleted guides (Supplementary Table 3) can be 
analyzed for significant clustering of gene categories. Gene categories exhibiting significant 
depletion based on Ingenuity Pathway Analysis (p<0.01 after B-H FDR correction) are 
shown. Categories based on the 1000 most depleted guides individually (left) and the 
average of all 3 guides/gene (right). These categories include either positive or negative 
regulators of each pathway that reduce proliferation and survival.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Structure-guided design and optimization of an RNA-guided transcription activation 
complex
a, A crystal structure of the Cas9-sgRNA-target DNA tertiary complex (PDB ID: 4OO8)14 
reveals that the sgRNA tetraloop and stem loop 2 are exposed. b, Schematic of the three-
component SAM system. c, Design and optimization of sgRNA scaffolds for optimal 
recruitment of MS2-VP64 transactivators in Neuro-2a cells. d, MS2 stem-loop placement 
within the sgRNA significantly affects transcription activation efficiency. e, Combinations 
of different activation domains act in synergy to enhance the level of transcription 
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activation. f, Addition of the HSF1 transactivation domain to MS2-p65 further increases the 
efficiency of transcription activation. Experiments for d-f were performed in 293FT cells. 
All values are mean ± SEM with n = 3. * indicates p <0.05 based on Student’s t-test.
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Figure 2. Characterization of SAM-mediated gene and lincRNA activation and derivation of 
selection rules for efficient sgRNAs
a, Fold activation of 12 different genes plotted against the sgRNA location. sgRNA 1.0 with 
dCas9-VP64 (grey), sgRNA 2.0 with dCas9-VP64 and MS2-p65-HSF1 (blue). b, 
Comparison of activation efficiency of 12 target genes: dCas9-VP64 and a single sgRNA 
1.0; dCas9-VP64 with a single sgRNA 2.0 and MS2-p65-HSF1, and dCas9-VP64 with a 
mixture of 8 sgRNA 1.0s. c, Efficiency of target gene activation as a function of baseline 
expression levels. d, Correlation of gene activation efficiency with sgRNA targeting 
position. Activation efficiency of each sgRNA for the same target gene is normalized 
against the highest-activating sgRNA. e, Fold activation of six lincRNA transcripts by SAM 
(best sgRNA out of 8 tested). All experiments were performed in 293FT cells. All values are 
mean ± SEM with n = 3.
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Figure 3. Simultaneous activation of endogenous genes using multiplexed sgRNA expression
a, Activation of individual genes by single sgRNAs with dCas9-VP64 and MS2-p65-HSF1. 
b, Simultaneous activation of the same ten genes using a mixture of ten sgRNAs each 
targeting a different gene. c, Effect of sgRNA dilution on gene activation efficiency. d, 
Correlation between the activation efficiency of a single 10-fold diluted sgRNA and that of 
the same sgRNA delivered within a mixture of ten different-gene targeting sgRNAs. All 
values are mean ± SEM with n = 3.
Konermann et al. Page 33













Figure 4. Evaluation of SAM specificity
Expression levels in log(TPM) values of all detected genes in RNA-seq libraries of GFP-
transfected controls (x-axis of all graphs) compared to (from left to right): SAM targeting 
HBG1/2 genes in 1× dilution and 50× dilution, non-targeting control sgRNAs in 1× dilution 
and 50× dilution (y-axis). Marked are the two statistically significant differentially 
expressed genes (T-test q-value < 0.05 with FDR correction): HBG1 (red) and HGB2 (blue). 
The average from n = 3 is shown.
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Figure 5. Genome-scale gene activation screening identifies mediators of BRAF inhibitor 
resistance
a, Flow chart of transcription activation screening using SAM. b, Box plot showing the 
distribution of sgRNA frequencies post lentiviral transduction for baseline (day 3), vehicle 
(day 21), and PLX-4720 (day 21) conditions. c, Scatterplot showing enrichment of specific 
sgRNAs after PLX-4720 treatment. d, Identification of top candidate genes using the 
RIGER P value analysis based on the average of both infection replicates. e, Comparison of 
RIGER P values for the top 100 hits from SAM and GeCKO3 PLX-4720 resistance screens. 
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f, Consistency of sgRNAs for top screening hits. Fraction of unique sgRNAs targeting each 
gene that are in the top 5% of all sgRNAs is plotted.
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Figure 6. Validation of top hits from genome-scale gene activation screen for PLX-4720 
resistance mediators
a, Comparison of PLX-4720 resistance, transcription activation and protein upregulation in 
A375 cells for top screening hits. b, Expression levels of top hits and screen signatures are 
elevated in the resistant state of short-term BRAFV600 melanoma cultures (see Methods for 
signature generation). The subset of samples which were previously tested for PLX-4720 
sensitivity and resistance are indicated by blue and red arrows respectively39. IC: 
Information Coefficient. All values are mean ± SEM with n = 3.
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